A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy

Biomaterials

Volumn 32, Issue 11, 2011, Pages 3124-3133

  Mao, Cheng Qiong ^a   Du, Jin Zhi ^b   Sun, Tian Meng ^a   Yao, Yan Dan ^c   Zhang, Pei Zhuo ^d   Song, Er Wei ^c   Wang, Jun ^a  

^a University of Science and Technology of China   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d Suzhou GenePharma Co Ltd   (China)

Author keywords

Acid ceramidase; Cancer therapy; Micelleplex; Polyphosphoester; SiRNA delivery

Indexed keywords

ACID CERAMIDASE; CANCER THERAPY; MICELLEPLEX; POLYPHOSPHOESTERS; SIRNA DELIVERY;

BLOCK COPOLYMERS; CELL DEATH; COPOLYMERIZATION; DISEASES; ETHYLENE; ETHYLENE GLYCOL; NUCLEIC ACIDS; ONCOLOGY; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; RNA; TUMORS; ZETA POTENTIAL;

GENE THERAPY;

ACID CERAMIDASE; COPOLYMER; MACROGOL; NANOPARTICLE; POLY(2 AMINOETHYL ETHYLENE PHOSPHATE); POLYCAPROLACTONE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CONTROLLED STUDY; FEMALE; GENE TARGETING; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; ZETA POTENTIAL;

ACID CERAMIDASE; ANIMALS; APOPTOSIS; BIOCOMPATIBLE MATERIALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MICELLES; NANOPARTICLES; POLYMERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

MURINAE;

EID: 79951581352     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.01.006     Document Type: Article

References (58)

1. Landthaler M., Yalcin A., Tuschl T. The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol 2004, 14(23):2162-2167.
2. McCaffrey A., Nakai H., Pandey K., Huang Z., Salazar F., Xu H., et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003, 21:639-644.
3. Jacque J., Triques K., Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002, 418:435-438.
4. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004, 351:1772.
5. Kim D., Rossi J. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007, 8:173-184.
6. Hannon G., Rossi J. Unlocking the potential of the human genome with RNA interference. Nature 2004, 431:371-378.
7. Michienzi A., Castanotto D., Lee N., Li S., Zaia J., Rossi J. RNA-mediated inhibition of HIV in a gene therapy setting. Ann Ny Acad Sci 2003, 1002. Therapeutic Oligonucleotides: Antisense, RNAi, Triple-Helix, Gene Repair, Enhancer Decoys, CpG and DNA Chips): pp. 63-71.
8. Raoul C., Abbas-Terki T., Bensadoun J., Guillot S., Haase G., Szulc J., et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005, 11(4):423-428.
9. Minakuchi Y., Takeshita F., Kosaka N., Sasaki H., Yamamoto Y., Kouno M., et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004, 32:e109.
10. Medarova Z., Pham W., Farrar C., Petkova V., Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007, 13:372-377.
11. Song E., Zhu P., Lee S., Chowdhury D., Kussman S., Dykxhoorn D., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005, 23:709-717.
12. Dykxhoorn D., Lieberman J. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu Rev Biomed Eng 2006, 8:377-402.
13. De Fougerolles A., Vornlocher H., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443-453.
14. Juliano R., Bauman J., Kang H., Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharmaceut 2009, 6:686-695.
15. Castanotto D., Rossi J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457:426-433.
16. Bartlett D., Su H., Hildebrandt I., Weber W., Davis M. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007, 104:15549.
17. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E., Busini V., Hossain N., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008, 26:561-569.
18. Kumar P., Wu H., McBride J., Jung K., Kim M., Davidson B., et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39-43.
19. Zhang S., Zhao B., Jiang H., Wang B., Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 2007, 123:1-10.
20. Gao K., Huang L. Nonviral methods for siRNA delivery. Mol Pharmaceut 2008, 6:651-658.
21. Davis M. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharmaceut 2009, 6:659-668.
22. Alshamsan A., Haddadi A., Incani V., Samuel J., Lavasanifar A., Uludag H. Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol Pharmaceut 2008, 6:121-133.
23. Kumar P., Ban H., Kim S., Wu H., Pearson T., Greiner D., et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008, 134:577-586.
24. Rothdiener M., Müller D., Castro P., Scholz A., Schwemmlein M., Fey G., et al. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release 2010, 144:251-258.
25. Li S., Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharmaceut 2006, 3:579-588.
26. Qiu L., Bae Y. Self-assembled polyethylenimine-graft-poly ([epsilon]-caprolactone) micelles as potential dual carriers of genes and anticancer drugs. Biomaterials 2007, 28:4132-4142.
27. Shuai X., Merdan T., Unger F., Wittmar M., Kissel T. Novel biodegradable ternary copolymers hy-PEI-g-PCL-b-PEG: synthesis, characterization, and potential as efficient nonviral gene delivery vectors. Macromolecules 2003, 36:5751-5759.
28. Wang Y., Gao S., Ye W., Yoon H., Yang Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
29. Wang Y., Wang L., Goh S., Yang Y. Synthesis and characterization of cationic micelles self-assembled from a biodegradable copolymer for gene delivery. Biomacromolecules 2007, 8:1028-1037.
30. Wang Y., Ke C., Weijie Beh C., Liu S., Goh S., Yang Y. The self-assembly of biodegradable cationic polymer micelles as vectors for gene transfection. Biomaterials 2007, 28:5358-5368.
31. Zhu C., Jung S., Luo S., Meng F., Zhu X., Park T., et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 2010, 31:2408-2416.
32. Segura T., Hubbell J. Synthesis and in vitro characterization of an ABC triblock copolymer for siRNA delivery. Bioconjug Chem 2007, 18:736-745.
33. Xiong X., Uludag H., Lavasanifar A. Biodegradable amphiphilic poly (ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. Biomaterials 2009, 30:242-253.
34. Sun T., Du J., Yan L., Mao H., Wang J. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials 2008, 29:4348-4355.
35. Saad A., Meacham W., Bai A., Anelli V., Elojeimy S., Mahdy A., et al. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 2007, 6:1455.
36. Zeidan Y., Jenkins R., Korman J., Liu X., Obeid L., Norris J., et al. Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets 2008, 9:653-661.
37. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002, 110:3-8.
38. Huwiler A., Zangemeister-Wittke U. Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit Rev Oncol Hematol 2007, 63:150-159.
39. Morales A., Paris R., Villanueva A., Llacuna L., Garcia-Ruiz C., Fernandez-Checa J. Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene 2006, 26:905-916.
40. Wang Y., Liu X., Sun T., Xiong M., Wang J. Functionalized micelles from block copolymer of polyphosphoester and poly (-caprolactone) for receptor-mediated drug delivery. J Control Release 2008, 128:32-40.
41. Diezi T., Bae Y., Kwon G. Enhanced stability of PEG-block-poly (N-hexyl stearate L-aspartamide) micelles in the presence of serum proteins. Mol Pharmaceut 2010, 7:1355-1360.
42. Noh S., Park M., Shim G., Han S., Lee H., Huh J., et al. Pegylated poly-l-arginine derivatives of chitosan for effective delivery of siRNA. J Control Release 2010, 145:159-164.
43. Kim J., Taluja A., Knutson K., Han Bae Y. Stability of bovine serum albumin complexed with PEG-poly (l-histidine) diblock copolymer in PLGA microspheres. J Control Release 2005, 109:86-100.
44. Li Q., Wang J., Shahani S., Sun D., Sharma B., Elisseeff J., et al. Biodegradable and photocrosslinkable polyphosphoester hydrogel. Biomaterials 2006, 27:1027-1034.
45. Wachiralarpphaithoon C., Iwasaki Y., Akiyoshi K. Enzyme-degradable phosphorylcholine porous hydrogels cross-linked with polyphosphoesters for cell matrices. Biomaterials 2007, 28:984-993.
46. Selzner M., Bielawska A., Morse M., Rüdiger H., Sindram D., Hannun Y., et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001, 61:1233.
47. Cohen G., Sun X., Snowden R., Dinsdale D., Skilleter D. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem J 1992, 286:331.
48. Ormerod M., Paul F., Cheetham M., Sun X. Discrimination of apoptotic thymocytes by forward light scatter. Cytom Part A 1995, 21:300-304.
49. Li P., Nijhawan D., Budihardjo I., Srinivasula S., Ahmad M., Alnemri E., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
50. Cheng E., Wei M., Weiler S., Flavell R., Mak T., Lindsten T., et al. BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 2001, 8:705-711.
51. Gross A., Yin X., Wang K., Wei M., Jockel J., Milliman C., et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999, 274:1156-1163.
52. Cardone M., Roy N., Stennicke H., Salvesen G., Franke T., Stanbridge E., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321.
53. Reiners J., Caruso J., Mathieu P., Chelladurai B., Yin X., Kessel D. Release of cytochrome c and activation of pro-caspase-9 following lysosomal photodamage involves bid cleavage. Cell Death Differ 2002, 9:934-944.
54. Hu Y., Benedict M., Wu D., Inohara N., Nú ez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci U S A 1998, 95:4386-4391.
55. Krajewski S., Krajewska M., Ellerby L., Welsh K., Xie Z., Deveraux Q., et al. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. Proc Natl Acad Sci U S A 1999, 96:5752-5757.
56. Poeck H., Besch R., Maihoefer C., Renn M., Tormo D., Morskaya S., et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008, 14:1256-1263.
57. Judge A., Sood V., Shaw J., Fang D., McClintock K., MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23:457-462.
58. Marques J., Williams B. Activation of the mammalian immune system by siRNAs. Nat Biotechnol 2005, 23:1399-1405.